Integrated product development is becoming an increasingly important strategy for successfully bringing a new drug to the market. It offers a path to the transformation of drug development by having various departments work collaboratively to devise a single integrated drug development strategy.
PharmaLex recently conducted a survey of 107 US respondents at director level and above across a wide range of pharmaceutical and biotechnology companies to understand where organizations are on their IPD journey. The webinar shares key insights from the survey and explores what these mean for industry
Vice President, Principal Consultant
Development Consulting & Scientific Affairs
An expert in global drug development Mark has over 30 years of experience in life sciences. His product development experience spans small molecules, biologics, biosimilars and medical devices across multiple therapy areas. Understanding what it takes to deliver new drugs to the market his expertise includes clinical and regulatory strategy, regulatory agency meetings, and program, project and portfolio management.
Senior Director, Head Integrated Product Development & Consulting
Head Swiss Operations & Qualified Person
Frederic brings to the role more than 16 years’ experience in the pharmaceutical industry, together with 10+ years’ experience as a Consultant, which has given him extensive experience of what is expected from Agencies from pre-filing dialogue to the granting and maintenance of Marketing Authorizations. During this time, Frederic has gained an in-depth knowledge of development and regulatory requirements and he has prepared and driven numerous meetings with Health Authorities/bodies, including for National and European Scientific Advice.